Mesoblast Appoints Leading Pharmaceutical Industry Executive as Chief Medical Officer
August 12 2019 - 6:00AM
Mesoblast Limited (Nasdaq: MESO; ASX: MSB), global leader in
cellular medicines for inflammatory diseases, is pleased to
announce the appointment of Dr Fred Grossman as Chief Medical
Officer (CMO), based in New York. Dr Grossman brings a wealth of
commercial experience gained from numerous leadership roles at
global pharmaceutical companies. The appointment aligns closely
with the Company’s commercial objectives for its lead products.
Dr Grossman has over 20 years of industry experience,
and has held key leadership positions at major global
pharmaceutical companies, including Eli Lilly, Johnson &
Johnson (J&J), Bristol Myers Squibb (BMS), Sunovion, and
Glenmark. During his career, he has managed global
clinical development, pharmacovigilance, medical affairs and
clinical operations for innovative product development, as well
as United States Food and Drug Administration (FDA) approvals
and post-market support for numerous blockbuster, specialty and
generic products. Dr Grossman has led and built teams in
the United States, Europe and Japan with responsibility for global
medical affairs, global clinical development, health economics
& outcomes research (HEOR) and global drug safety.
At J&J and Eli Lilly, Dr Grossman was responsible for
multiple New Drug Applications (NDAs) to the FDA. At BMS, he was
Global Head of the Medical Affairs organization, with focus on
immunology and cardiovascular diseases. As Head of Clinical
Development, Medical Affairs & Drug Safety at 6,000-person
global pharma Sunovion, a subsidiary of Japan’s Sumitomo
Dainippon Pharma Co., Dr Grossman had responsibility
across teams in the United States, Europe and Japan and
successfully launched a blockbuster product in the United States
market. More recently, he was CMO at Glenmark, an India-based
global pharma with 12,000 people, where he oversaw a portfolio
spanning biologics, branded drugs, and generics, including in
immunology and immuno-oncology.
Dr Grossman said: “I am very excited to have the opportunity of
working at Mesoblast, a very innovative company with a mature
pipeline of cellular medicines that have the potential to address
some of the most severe diseases affecting people worldwide. I look
forward to utilizing the experience gained from many product
launches to ensure that Mesoblast successfully transitions to a
commercial organization with the planned launch of its first
product in the United States.”
Mesoblast Chief Executive Dr Silviu Itescu thanked outgoing CMO
Dr Donna Skerrett for her valuable contributions during the
Company’s development stages. Dr Skerrett will continue in an
advisory role.
Dr Itescu welcomed Dr Grossman to the Company, stating: “Fred
brings to Mesoblast extensive industry experience which is
extremely valuable to the strategic and execution phases of our
commercial transition as we prepare for our first FDA Biologics
License Application (BLA) and commercial product launch in the
United States market. His strong track record of building
high-performing teams and setting corporate culture make him
ideally suited to lead our late-stage product development
strategies and commercial execution.”
About MesoblastMesoblast Limited (Nasdaq: MESO;
ASX: MSB) is a world leader in developing allogeneic
(off-the-shelf) cellular medicines. The Company has leveraged its
proprietary technology platform to establish a broad portfolio of
late-stage product candidates with three product candidates in
Phase 3 trials – acute graft versus host disease, chronic heart
failure and chronic low back pain due to degenerative disc disease.
Through a proprietary process, Mesoblast selects rare mesenchymal
lineage precursor and stem cells from the bone marrow of healthy
adults and creates master cell banks, which can be industrially
expanded to produce thousands of doses from each donor without the
need for tissue matching. Mesoblast has facilities in Melbourne,
New York, Singapore and Texas and is listed on the Australian
Securities Exchange (MSB) and on the Nasdaq (MESO).
www.mesoblast.com
Forward-Looking Statements This announcement
includes forward-looking statements that relate to future events or
our future financial performance and involve known and unknown
risks, uncertainties and other factors that may cause our actual
results, levels of activity, performance or achievements to differ
materially from any future results, levels of activity, performance
or achievements expressed or implied by these forward-looking
statements. We make such forward-looking statements pursuant to the
safe harbor provisions of the Private Securities Litigation Reform
Act of 1995 and other federal securities laws. Forward-looking
statements should not be read as a guarantee of future performance
or results, and actual results may differ from the results
anticipated in these forward-looking statements, and the
differences may be material and adverse. Forward-looking statements
include, but are not limited to, statements about the timing,
progress and results of Mesoblast’s preclinical and clinical
studies in aGVHD; Mesoblast’s ability to advance its aGVHD product
candidate into, enroll and successfully complete, clinical studies;
the timing or likelihood of regulatory filings and approvals for
aGVHD; and the pricing and reimbursement of Mesoblast’s product
candidates, if approved. You should read this press release
together with our risk factors, in our most recently filed reports
with the SEC or on our website. Uncertainties and risks that may
cause Mesoblast’s actual results, performance or achievements to be
materially different from those which may be expressed or implied
by such statements, and accordingly, you should not place undue
reliance on these forward-looking statements. We do not undertake
any obligations to publicly update or revise any forward-looking
statements, whether as a result of new information, future
developments or otherwise.
For further information, please contact:
Julie MeldrumCorporate CommunicationsT: +61 3 9639 6036E:
julie.meldrum@mesoblast.com
Schond Greenway Investor Relations T: +1 212 880 2060 E:
schond.greenway@mesoblast.com
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/56a8b5c9-1e2f-41c1-863e-c1d753d09e10
Mesoblast (NASDAQ:MESO)
Historical Stock Chart
From May 2024 to Jun 2024
Mesoblast (NASDAQ:MESO)
Historical Stock Chart
From Jun 2023 to Jun 2024